Adverse Events Associated with Hormonal Therapy for Prostate Cancer

Overview

Journal Rev Urol

Date 2006 Sep 21

PMID 16985883

Citations 38

Authors

Ravi J Kumar

Al Barqawi

E David Crawford

Affiliations

Soon will be listed here.

Abstract

With expanding indications for androgen deprivation therapy for the treatment of prostate cancer, it is imperative that health care providers be cognizant of the possible adverse effects of therapy, as well as their prevention and treatment. Neurologic and psychiatric effects include depression and declines in cognitive function. Musculoskeletal effects of hormonal therapy include osteoporosis, decrease in muscle mass, and fatigue. Gynecomastia, weight gain, and erectile dysfunction are also seen, as are hematologic effects. Further research is needed to evaluate alternative forms of therapy, such as intermittent hormonal deprivation and antiandrogen monotherapy.

Citing Articles

Hormones as a double-edged sword: the role of hormones in cancer progression and the potential of targeted hormone therapies.

Joshi D, Patel J, Munshi M, Mistry Z, Prajapati A, Mukherjee A Med Oncol. 2024; 41(11):283.

PMID: 39400627 DOI: 10.1007/s12032-024-02517-z.

Chemotherapy periodization to maximize resistance training adaptations in oncology.

Nunes J, Cella P, Guimaraes T, Bucu I, Deminice R Cancer Chemother Pharmacol. 2023; 92(5):357-367.

PMID: 37582913 DOI: 10.1007/s00280-023-04576-x.

Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers.

Garrido M, Hernandez A, Vega M, Araya E, Romero C Front Endocrinol (Lausanne). 2023; 14:1143261.

PMID: 37056674 PMC: 10086188. DOI: 10.3389/fendo.2023.1143261.

Case - Leuprolide acetate-induced necrotic skin ulceration.

Janes W, Ogunyemi B, Andrews M Can Urol Assoc J. 2022; 17(3):E92-E94.

PMID: 36473470 PMC: 10027351. DOI: 10.5489/cuaj.8112.

A Web-Based Prostate Cancer-Specific Holistic Needs Assessment (CHAT-P): Multimethod Study From Concept to Clinical Practice.

Nanton V, Appleton R, Ahmed N, Loew J, Roscoe J, Muthuswamy R JMIR Cancer. 2022; 8(4):e32153.

PMID: 36260380 PMC: 9624375. DOI: 10.2196/32153.

References

Cervenakov I, Kopecny M, Jancar M, Chovan D, Mala M . 'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate. Int Urol Nephrol. 2000; 32(1):77-9. DOI: 10.1023/a:1007164319067. View

Barrett-Connor E, Patay B . Endogenous sex hormones and cognitive function in older men. J Clin Endocrinol Metab. 1999; 84(10):3681-5. DOI: 10.1210/jcem.84.10.6086. View

Tamir S, Eizenberg M, Somjen D, IZRAEL S, Vaya J . Estrogen-like activity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol. 2001; 78(3):291-8. DOI: 10.1016/s0960-0760(01)00093-0. View

Seidell J, Bjorntorp P, Sjostrom L, Kvist H, SANNERSTEDT R . Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990; 39(9):897-901. DOI: 10.1016/0026-0495(90)90297-p. View

Riggs B, Atkinson E, OFallon W, Eastell R, Khosla S . Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000; 106(12):1553-60. PMC: 381474. DOI: 10.1172/JCI10942. View

Loprinzi C, Michalak J, Quella S, OFallon J, Hatfield A, Nelimark R . Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994; 331(6):347-52. DOI: 10.1056/NEJM199408113310602. View

Quella S, Loprinzi C, Sloan J, Novotny P, Perez E, Burch P . Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol. 1999; 162(1):98-102. DOI: 10.1097/00005392-199907000-00024. View

Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A . Combination treatment versus LHRH alone in advanced prostatic cancer. Urol Int. 1996; 56 Suppl 1:13-7. DOI: 10.1159/000282863. View

Gillatt D, Bolton C, Chadwick D, Downs L, Hopton M, Gingell J . Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues. Br J Urol. 1993; 71(6):728-30. DOI: 10.1111/j.1464-410x.1993.tb16074.x. View

10.

Srinivasan V, MIREE Jr J, LLOYD F . Bilateral mastectomy and irradiation in the prevention of estrogen induced gynecomastia. J Urol. 1972; 107(4):624-5. DOI: 10.1016/s0022-5347(17)61097-8. View

11.

Green H, Pakenham K, Headley B, Yaxley J, Nicol D, Mactaggart P . Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002; 90(4):427-32. DOI: 10.1046/j.1464-410x.2002.02917.x. View

12.

Strum S, McDermed J, Scholz M, Johnson H, Tisman G . Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997; 79(6):933-41. DOI: 10.1046/j.1464-410x.1997.00234.x. View

13.

Jeffery S, Pepe J, Popovich L, Vitagliano G . Gabapentin for hot flashes in prostate cancer. Ann Pharmacother. 2002; 36(3):433-6. DOI: 10.1345/aph.1A139. View

14.

Smith M, Finkelstein J, McGovern F, Zietman A, Fallon M, Schoenfeld D . Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002; 87(2):599-603. DOI: 10.1210/jcem.87.2.8299. View

15.

Loblaw D, Mendelson D, Talcott J, Virgo K, Somerfield M, Ben-Josef E . American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004; 22(14):2927-41. DOI: 10.1200/JCO.2004.04.579. View

16.

Smith M, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169(6):2008-12. DOI: 10.1097/01.ju.0000063820.94994.95. View

17.

Spetz A, Hammar M, Lindberg B, Spangberg A, Varenhorst E . Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol. 2001; 166(2):517-20. View

18.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

19.

Langenstroer P, Porter 2nd H, McLeod D, Thrasher J . Direct gastrointestinal toxicity of flutamide: comparison of irradiated and nonirradiated cases. J Urol. 2004; 171(2 Pt 1):684-6. DOI: 10.1097/01.ju.0000106835.60202.81. View

20.

Stepan J, Lachman M, Zverina J, Pacovsky V, Baylink D . Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab. 1989; 69(3):523-7. DOI: 10.1210/jcem-69-3-523. View